The same effect of the combination treatment was exhibited in breast cancer patient-derived organoids (PDOs), and it was suggested the mechanism for this was through preventing ET-1’s induction of HIF-1α expression, thus preventing the angiogenic pathway via the ET-1/ETBR axis [38]. This evidence concerns the gene HIF1A and breast carcinoma.